Viatris (VTRS)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-07
$16.96+0.95%
Close 2026-07-07 · 1-day change
Reading VTRS? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track VTRS free→NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-07
Reading VTRS? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track VTRS free→QuarterlyIQ Insights · VTRS
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $16.96. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $17 VTRS trades at 6.9× p/e, below its 25× p/e peer median. Our $21 fair value sits above the price. We hold it with low confidence: it trades at 1.6× its own p/e history and the peer anchor overstates how cheap it looks. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| Peer P/FCF | 12M | $24.58 | 16.9 | 1.45 | TTM | high |
| Peer P/E | 12M | $61.65 | 25.2 | 2.45 | TTM | high |
| Peer P/S | 12M | $31.60 | 2.6 | 12.39 | TTM | high |
| PEG | 12M | $13.80 | 5.6 | 2.45 | TTM | high |
| Own P/E history | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 4% over what the business is worth with no growth; closing that gap needs roughly — years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $1.61/sh owner earnings.
Looks cheaper than most peers in the same business.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $10.70 |
| 4.4 |
| 2.45 |
| TTM |
| high |
| triangulated | 12M | $59.91 | 25.2 | 2.38 | Triangulated | high |
| Peer P/FCF | 3Y | $18.02 | 16.9 | 1.07 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $73.08 | 25.2 | 2.90 | Analyst | medium |
| Peer P/S | 3Y | $33.12 | 2.6 | 12.99 | guidance | medium |
| PEG | 3Y | $16.36 | 5.6 | 2.90 | Analyst | medium |
| Own P/E history | 3Y | $12.69 | 4.4 | 2.90 | Analyst | medium |
| Peer P/FCF | 5Y | $14.65 | 16.9 | 0.87 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $81.85 | 25.2 | 3.25 | Analyst | high |
| Peer P/S | 5Y | $33.75 | 2.6 | 13.23 | guidance | high |
| PEG | 5Y | $18.32 | 5.6 | 3.25 | Analyst | high |
| Own P/E history | 5Y | $14.21 | 4.4 | 3.25 | Analyst | high |